Nuvalent (NUVL) 10-Q 11 May 23 2023 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2023	Apr. 28, 2023
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Entity File Number	001-40671
Entity Registrant Name	NUVALENT, INC.
Entity Central Index Key	0001861560
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	81-5112298
Entity Address, Address Line One	One Broadway
Entity Address, Address Line Two	14th Floor
Entity Address, City or Town	Cambridge
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02142
City Area Code	857
Local Phone Number	357-7000
Title of 12(b) Security	Class A Common Stock, par value $0.0001 per share
Trading Symbol	NUVL
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Common Class A [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		51,385,516
Common Class B [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		5,435,254

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 90,115	$ 241,806
Marketable securities	360,347	230,357
Prepaid expenses and other current assets	5,831	5,828
Total current assets	456,293	477,991
Other assets	4,696	4,468
Total assets	460,989	482,459
Current liabilities:
Accounts payable	6,433	7,195
Accrued expenses	10,588	12,286
Total current liabilities	17,021	19,481
Total liabilities	17,021	19,481
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding	0	0
Additional paid-in capital	629,533	623,543
Accumulated other comprehensive loss	(302)	(494)
Accumulated deficit	(185,269)	(160,077)
Total stockholders' equity	443,968	462,978
Total liabilities and stockholders' equity	460,989	482,459
Common Class A [Member]
Stockholders' equity:
Common stock	5	5
Common Class B [Member]
Stockholders' equity:
Common stock	$ 1	$ 1

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Preferred stock, par value | $ / shares	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common Class A [Member]
Common stock, par value | $ / shares	$ 0.0001	$ 0.0001
Common stock, shares authorized	140,000,000	140,000,000
Common stock, shares issued	51,316,690	51,233,701
Common stock, shares outstanding	51,316,690	51,233,701
Common Class B [Member]
Common stock, par value | $ / shares	$ 0.0001	$ 0.0001
Common stock, shares authorized	10,000,000	10,000,000
Common stock, shares issued	5,435,254	5,435,254
Common stock, shares outstanding	5,435,254	5,435,254

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating expenses:
Research and development	$ 22,125	$ 12,693
General and administrative	8,085	4,995
Total operating expenses	30,210	17,688
Loss from operations	(30,210)	(17,688)
Other income (expense):
Interest income and other income, net	5,018	139
Total other income, net	5,018	139
Net loss	$ (25,192)	$ (17,549)
Net loss per share attributable to common stockholders, basic	$ (0.44)	$ (0.36)
Net loss per share attributable to common stockholders, diluted	$ (0.44)	$ (0.36)
Weighted average shares of common stock outstanding, basic	56,703,873	48,284,778
Weighted average shares of common stock outstanding, diluted	56,703,873	48,284,778
Comprehensive loss:
Net loss	$ (25,192)	$ (17,549)
Other comprehensive income (loss):
Unrealized gains (losses) on marketable securities	192	(791)
Comprehensive loss	$ (25,000)	$ (18,340)

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common stock [Member] Common Class A [Member]	Common stock [Member] Common Class B [Member]	Additional paid-in capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated deficit [Member]
Beginning Balance , Shares at Dec. 31, 2021		42,862,175	5,435,254
Beginning Balance at Dec. 31, 2021	$ 285,037	$ 4	$ 1	$ 363,483	$ (228)	$ (78,223)
Issuance of common stock upon exercise of stock options , Shares		16,572
Issuance of common stock upon exercise of stock options	13			13
Unrealized losses on marketable securities	(791)				(791)
Stock-based compensation expense	2,205			2,205
Net loss	(17,549)					(17,549)
Ending Balance , Shares at Mar. 31, 2022		42,878,747	5,435,254
Ending Balance at Mar. 31, 2022	268,915	$ 4	$ 1	365,701	(1,019)	(95,772)
Beginning Balance , Shares at Dec. 31, 2021		42,862,175	5,435,254
Beginning Balance at Dec. 31, 2021	285,037	$ 4	$ 1	363,483	(228)	(78,223)
Net loss	(81,900)
Ending Balance , Shares at Dec. 31, 2022		51,233,701	5,435,254
Ending Balance at Dec. 31, 2022	462,978	$ 5	$ 1	623,543	(494)	(160,077)
Issuance of common stock upon exercise of stock options , Shares		82,989
Issuance of common stock upon exercise of stock options	619			619
Unrealized losses on marketable securities	192				192
Stock-based compensation expense	5,371			5,371
Net loss	(25,192)					(25,192)
Ending Balance , Shares at Mar. 31, 2023		51,316,690	5,435,254
Ending Balance at Mar. 31, 2023	$ 443,968	$ 5	$ 1	$ 629,533	$ (302)	$ (185,269)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net loss	$ (25,192)	$ (17,549)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	5,371	2,205
Net amortization (accretion) of premiums (discounts) on marketable securities	(2,538)	276
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(3)	778
Other assets	(228)	630
Accounts payable	(672)	1,353
Accrued expenses	(1,152)	(1,235)
Net cash used in operating activities	(24,414)	(13,542)
Cash flows from investing activities:
Purchases of marketable securities	(187,948)	(13,943)
Proceeds from sales and maturities of marketable securities	60,688	27,000
Net cash provided by (used in) investing activities	(127,260)	13,057
Cash flows from financing activities:
Payments of insurance costs financed by a third-party	(546)	(781)
Proceeds from issuance of common stock upon option exercise	619	13
Payments of offering costs	(90)
Net cash used in financing activities	(17)	(768)
Net decrease in cash and cash equivalents	(151,691)	(1,253)
Cash and cash equivalents at beginning of period	241,806	68,526
Cash and cash equivalents at end of period	$ 90,115	$ 67,273

Nature of Business and Basis of

Nature of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business and Basis of Presentation	1. Nature of Business and Basis of Presentation Nuvalent, Inc. (the “Company”) is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. The Company was founded in January 2017 as a Delaware corporation. The Company is headquartered in Cambridge, Massachusetts. The Company is subject to risks similar to those of other pre-commercial stage companies in the biopharmaceutical industry, including dependence on key individuals, the need to develop commercially viable products, competition from other companies, many of which are larger and better capitalized, the need to obtain adequate additional financing to fund the development of its product candidates, and the impact of COVID-19 and other global geopolitical events on the Company’s business. There can be no assurance that the Company’s research and development will be successful, that adequate protection for the Company’s intellectual property will be obtained and maintained, that any product candidates will receive required regulatory approval or that approved products, if any, will be commercially viable. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from the sale of its products. On November 3, 2022, the Company issued and sold 7,895,522 shares of Class A common stock, including the exercise in full by the underwriters of their option to purchase 1,029,850 additional shares of Class A common stock, in a follow-on public offering at a public offering price of $ 33.50 per share, resulting in net proceeds of $ 247.9 million after deducting underwriting discounts and commissions and offering costs. Basis of presentation The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Nuvalent Securities Corporation. All intercompany balances and transactions have been eliminated in consolidation. The Company has incurred recurring losses since inception, including net losses of $ 25.2 million for the three months ended March 31, 2023, and $ 81.9 million for the year ended December 31, 2022. As of March 31, 2023, the Company had an accumulated deficit of $ 185.3 million. The Company expects to continue to generate operating losses for the foreseeable future. The Company believes that its existing cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the date of issuance of these consolidated financial statements. The Company will need to obtain additional funding through public or private equity offerings, debt financings or strategic alliances. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders. Arrangements with collaborators or others may require the Company to relinquish rights to certain of its technologies or programs. If the Company is unable to obtain funding, the Company will be required to delay, reduce or eliminate some or all of its research and development programs or the Company may be unable to continue operations. Although management will continue to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations when needed or at all.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the valuation of stock-based awards and the accrual of research and development expenses. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions. Unaudited interim financial information The consolidated balance sheet at December 31, 2022, was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. The accompanying unaudited consolidated financial statements as of March 31, 2023, and for the three months ended March 31, 2023 and 2022, have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2022, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, on file with the SEC. In the opinion of management, these consolidated financial statements reflect all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the Company’s financial position as of March 31, 2023, and results of operations for the three months ended March 31, 2023 and 2022, and cash flows for the three months ended March 31, 2023 and 2022. The Company’s results of operations for the three months ended March 31, 2023, are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2023. Concentrations of credit risk and of significant suppliers Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company’s investments are comprised of commercial paper and corporate bonds of corporations and U.S. Treasury and U.S. government agency debt securities. As of March 31, 2023 and December 31, 2022, the Company maintained cash, cash equivalents and marketable securities balances in excess of federally insured limits. However, the Company mitigates credit risk by maintaining a diversified portfolio, placing its cash with high credit quality financial institutions and limiting the amount of investment exposure as to institution, maturity and investment type. The Company is dependent on third-party vendors for the manufacturing of its product candidates. In particular, the Company relies, and expects to continue to rely, on a small number of vendors to manufacture materials and components required for the production of its product candidates. These programs could be adversely affected by a significant interruption in the manufacturing process. Fair value measurements Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The Company’s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy described above (see Note 4). The carrying values of the Company’s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities. Marketable securities The Company’s marketable securities (non-equity instruments) are classified as available-for-sale and are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in stockholders’ equity. Realized gains and losses are based on the specific identification method and are included as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss. The Company classifies its marketable securities with maturities beyond one year as short-term, based on their highly liquid nature and because such marketable securities are available for current operations. Effective January 1, 2023, when the fair value is below the amortized cost of a marketable security, an estimate of expected credit losses is made. The credit-related impairment amount is recognized in the consolidated statements of operations and comprehensive loss. Credit losses are recognized through the use of an allowance for credit losses account in the consolidated balance sheet and subsequent improvements in expected credit losses are recognized as a reversal of an amount in the allowance account. If the Company intends to sell the security or it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis, then the allowance for the credit loss is written-off and the excess of the amortized cost basis of the asset over its fair value is recorded in the consolidated statements of operations and comprehensive loss. There were no credit losses recorded during the three months ended March 31, 2023. Net income (loss) per share Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding stock options and unvested restricted stock units. For periods in which the Company reported a net loss, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their affect is anti-dilutive. The Company has two classes of common stock outstanding: Class A common stock and Class B common stock. The rights of the holders of Class A and Class B common stock are substantially identical, except with respect to voting and conversion. Each share of Class B common stock is convertible into one share of Class A common stock at the option of the holder at any time, subject to the ownership limitations provided for in the Company’s amended and restated certificate of incorporation. The Company allocates undistributed earnings attributable to common stock between the common stock classes on a one-to-one basis when computing net income (loss) per share. As a result, basic and diluted net income (loss) per share of Class A common stock and share of Class B common stock are equivalent. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: As of March 31, 2023 2022 Unvested restricted common stock — 21,129 Options to purchase common stock 8,505,182 6,250,433 8,505,182 6,271,562 Recently adopted accounting pronouncements Effective January 1, 2023 , the Company adopted ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments for the year ended December 31, 2023. The new standard adjusts the accounting for assets held at amortized cost basis, including marketable securities accounted for as available for sale, and trade receivables. The standard eliminates the probable initial recognition threshold and requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. The adoption of this standard did no t have a material impact on the Company’s consolidated financial statements and related disclosures.

Marketable Securities

Marketable Securities	3 Months Ended
	Mar. 31, 2023
Marketable Securities [Abstract]
Marketable Securities	3. Marketable Securities Marketable securities by security type consisted of the following (in thousands): March 31, 2023 Amortized Gross Gross Fair Value Commercial paper (due within one year) $ 125,640 $ 52 $ ( 89 ) $ 125,603 Corporate bonds (due within one year) 78,062 7 ( 244 ) 77,825 Government securities (due within one year) 46,261 27 ( 45 ) 46,243 U.S. treasury securities (due within one year) 43,236 15 ( 10 ) 43,241 Corporate bonds (due after one year through three years) 34,534 26 ( 119 ) 34,441 Government securities (due after one year through 27,979 67 ( 5 ) 28,041 U.S. treasury securities (due after one year through 4,937 16 — 4,953 $ 360,649 $ 210 $ ( 512 ) $ 360,347 December 31, 2022 Amortized Gross Gross Fair Value Commercial paper (due within one year) $ 90,685 $ 1 $ ( 93 ) $ 90,593 Corporate bonds (due within one year) 70,668 1 ( 332 ) 70,337 Government securities (due within one year) 19,267 22 ( 28 ) 19,261 U.S. treasury securities (due within one year) 28,560 — ( 23 ) 28,537 Corporate bonds (due after one year through two years) 5,262 — ( 18 ) 5,244 Government securities (due after one year through 16,409 — ( 24 ) 16,385 $ 230,851 $ 24 $ ( 518 ) $ 230,357

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. Fair Value Measurements The following tables present the Company’s fair value hierarchy for its assets, which are measured at fair value on a recurring basis (in thousands): Fair Value Measurements at March 31, 2023: Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 79,079 $ — $ — $ 79,079 Marketable securities: Commercial paper — 125,603 — 125,603 Corporate bonds — 112,266 — 112,266 Government securities — 74,284 — 74,284 U.S. treasury securities — 48,194 — 48,194 $ 79,079 $ 360,347 $ — $ 439,426 Fair Value Measurements at December 31, 2022: Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 240,803 $ — $ — $ 240,803 Marketable securities: Commercial paper — 90,593 — 90,593 Corporate bonds — 75,581 — 75,581 Government securities — 35,646 — 35,646 U.S. treasury securities — 28,537 — 28,537 $ 240,803 $ 230,357 $ — $ 471,160 Money market funds were valued by the Company based on quoted market prices for identical securities, which represent a Level 1 measurement within the fair value hierarchy. Commercial paper, corporate bonds, government securities and U.S. treasury securities were valued by the Company using quoted prices in active markets for similar securities, which represent a Level 2 measurement within the fair value hierarchy. During the three months ended March 31, 2023 and 2022, there were no transfers in or out of Level 3.

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2023
Accrued Liabilities, Current [Abstract]
Accrued Expenses	5. Accrued Expenses Accrued expenses consisted of the following (in thousands): March 31, 2023 December 31, 2022 Accrued employee compensation and benefits $ 2,132 $ 4,852 Accrued external research and development expenses 7,469 5,944 Other 987 1,490 $ 10,588 $ 12,286

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2023
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	6. Stock-Based Compensation 2021 stock option and incentive plan On July 23, 2021, the Company’s board of directors adopted and its stockholders approved the 2021 Stock Option and Incentive Plan (the “2021 Plan”), which became effective on July 28, 2021. The 2021 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock units, unrestricted stock awards, cash-based awards and dividend equivalent rights. The number of shares of Class A common stock reserved for issuance under the 2021 Plan shall be increased on each January 1 by 5.0 % of the number of shares of the Company’s Class A and Class B common stock outstanding on the immediately preceding December 31 or such lesser number of shares determined by the Company’s board of directors or compensation committee of the board of directors. The number of shares of Class A common stock reserved for issuance was increased by 2,833,447 shares effective as of January 1, 2023, in accordance with the provisions of the 2021 Plan described above. The shares of Class A common stock underlying any awards that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of stock, expired or are otherwise terminated (other than by exercise) under the 2021 Plan and the Company’s previously outstanding 2017 Stock Option and Grant Plan will be added back to the shares of Class A common stock available under the 2021 Plan. As of March 31, 2023, 6,360,795 shares of Class A common stock remained available for future issuance under the 2021 Plan. 2021 employee stock purchase plan On July 23, 2021, the Company’s board of directors adopted and its stockholders approved the 2021 Employee Stock Purchase Plan, which became effective on July 28, 2021. The Company’s board of directors approved the amendment and restatement of the 2021 Employee Stock Purchase Plan in its entirety on June 16, 2022 (as amended and restated, the “ESPP”). The ESPP permits eligible employees to purchase shares of Class A common stock at a discount and consists of consecutive, overlapping 12-month offering periods, each consisting of two six-month purchase periods beginning in December and June. On the first day of each offering period, the Company will grant to each employee who is enrolled in the ESPP an option to purchase up to a whole number of shares of Class A common stock. The purchase price of each of the shares purchased in a given purchase period will be 85 % of the closing price of a share of the Class A common stock on the first day of the offering period or the last day of the purchase period, whichever is lower. The number of shares of Class A common stock that may be issued under the ESPP will automatically increase on each January through January 1, 2031, by the least of (i) 473,064 shares of Class A common stock, (ii) 1 % of the number of shares of the Company’s Class A and Class B common stock outstanding on the immediately preceding December 31 or (iii) such lesser number of shares as determined by the administrator of the ESPP. The initial offering period of the ESPP commenced on December 1, 2022. The number of shares of Class A common stock reserved for issuance was increased by 473,064 shares effective as of January 1, 2023, in accordance with the provisions of the ESPP described above. During the three months ended March 31, 2023, no shares were sold under the ESPP, and as of March 31, 2023, 1,419,192 shares remained available for issuance and sale. Option grants During the three months ended March 31, 2023 the Company granted options to its employees and directors with service-based vesting for the purchase of an aggregate of 2,134,430 shares of Class A common stock with a total grant-date fair value of $ 41.7 million. Stock-based compensation The Company recorded stock-based compensation expense related to common stock options and restricted common stock in the following expense categories of its consolidated statements of operations and comprehensive loss (in thousands): Three Months Ended March 31, 2023 2022 Research and development expenses $ 2,513 $ 947 General and administrative expenses 2,858 1,258 $ 5,371 $ 2,205 As of March 31, 2023, total unrecognized compensation cost related to common stock options was $ 67.1 million, which is expected to be recognized over a weighted average period of 3.2 years.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. Commitments and Contingencies Leases The Company leases office space pursuant to a month-to month lease and as such categorizes all of its lease expense as short-term lease cost. During each of the three months ended March 31, 2023 and 2022, the Company recorded short-term lease costs of less than $ 0.1 million. Revenue share The Company has revenue sharing agreements with Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design Fund, IV, L.P. (collectively, “Deerfield”), each an investor in the Company, and the Company’s scientific founder to pay each of Deerfield and the scientific founder a low single digit percentage rate of net sales of certain commercial products. The payment obligation expires on the later of 12 years from the first commercial sale in a country or the expiration of the last-to-expire patent in that country for both Deerfield and the Company’s scientific founder. The Company accounts for this liability at fair value with changes recognized in the consolidated statements of operations and comprehensive loss. Given the early-stage nature of the underlying technology and inherent risks associated with obtaining regulatory approval and achieving commercialization, the Company ascribed no value to either of the revenue sharing agreements at inception and at March 31, 2023 and December 31, 2022. The Company currently does not have any net sales and as a result has paid no amounts under these agreements no r has the Company accrued any liability as of March 31, 2023 and December 31, 2022 under these agreements. Indemnification agreements In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.

Defined Contribution Plan

Defined Contribution Plan	3 Months Ended
	Mar. 31, 2023
Defined Contribution Plan [Abstract]
Defined Contribution Plan	8. Defined Contribution Plan The Company has a 401(k) defined contribution plan (the “401(k) Plan”) for its employees. Eligible employees may make pretax and after-tax contributions to the 401(k) Plan up to statutory limits. The Company has established a match program for employee contributions to the 401(k) Plan up to a maximum of six percent of the employee’s salary. For the three months ended March 31, 2023 and 2022, the Company recorded expense of $ 0.3 million and $ 0.1 million, respectively, related to these matching contributions.

Related Parties

Related Parties	3 Months Ended
	Mar. 31, 2023
Related Party Transactions [Abstract]
Related Parties	9. Related Parties The Company is obligated to pay low single digit percentage rates of net sales of certain commercial products to Deerfield and its scientific founder. As of March 31, 2023 and December 31, 2022, no products have been commercialized and no amounts have been paid or become due (see Note 7). In February 2017, the Company entered into a three-year consulting agreement with the scientific founder of the Company who is also a board member and a stockholder. The consulting agreement between the scientific founder and the Company continues at will. During each of the three months ended March 31, 2023 and 2022, the Company paid the scientific founder $ 0.1 million. As of March 31, 2023 and December 31, 2022, the Company had no accounts payable and less than $ 0.1 million in accounts payable, respectively, to the scientific founder.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Use of estimates	Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the valuation of stock-based awards and the accrual of research and development expenses. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.
Unaudited interim financial information	Unaudited interim financial information The consolidated balance sheet at December 31, 2022, was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. The accompanying unaudited consolidated financial statements as of March 31, 2023, and for the three months ended March 31, 2023 and 2022, have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2022, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, on file with the SEC. In the opinion of management, these consolidated financial statements reflect all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the Company’s financial position as of March 31, 2023, and results of operations for the three months ended March 31, 2023 and 2022, and cash flows for the three months ended March 31, 2023 and 2022. The Company’s results of operations for the three months ended March 31, 2023, are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2023.
Concentrations of credit risk and of significant suppliers	Concentrations of credit risk and of significant suppliers Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company’s investments are comprised of commercial paper and corporate bonds of corporations and U.S. Treasury and U.S. government agency debt securities. As of March 31, 2023 and December 31, 2022, the Company maintained cash, cash equivalents and marketable securities balances in excess of federally insured limits. However, the Company mitigates credit risk by maintaining a diversified portfolio, placing its cash with high credit quality financial institutions and limiting the amount of investment exposure as to institution, maturity and investment type. The Company is dependent on third-party vendors for the manufacturing of its product candidates. In particular, the Company relies, and expects to continue to rely, on a small number of vendors to manufacture materials and components required for the production of its product candidates. These programs could be adversely affected by a significant interruption in the manufacturing process.
Fair value measurements	Fair value measurements Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The Company’s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy described above (see Note 4). The carrying values of the Company’s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities.
Marketable securities	Marketable securities The Company’s marketable securities (non-equity instruments) are classified as available-for-sale and are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in stockholders’ equity. Realized gains and losses are based on the specific identification method and are included as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss. The Company classifies its marketable securities with maturities beyond one year as short-term, based on their highly liquid nature and because such marketable securities are available for current operations. Effective January 1, 2023, when the fair value is below the amortized cost of a marketable security, an estimate of expected credit losses is made. The credit-related impairment amount is recognized in the consolidated statements of operations and comprehensive loss. Credit losses are recognized through the use of an allowance for credit losses account in the consolidated balance sheet and subsequent improvements in expected credit losses are recognized as a reversal of an amount in the allowance account. If the Company intends to sell the security or it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis, then the allowance for the credit loss is written-off and the excess of the amortized cost basis of the asset over its fair value is recorded in the consolidated statements of operations and comprehensive loss. There were no credit losses recorded during the three months ended March 31, 2023.
Net income (loss) per share	Net income (loss) per share Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding stock options and unvested restricted stock units. For periods in which the Company reported a net loss, diluted net loss per common share is the same as basic net loss per common share, since dilutive common shares are not assumed to have been issued if their affect is anti-dilutive. The Company has two classes of common stock outstanding: Class A common stock and Class B common stock. The rights of the holders of Class A and Class B common stock are substantially identical, except with respect to voting and conversion. Each share of Class B common stock is convertible into one share of Class A common stock at the option of the holder at any time, subject to the ownership limitations provided for in the Company’s amended and restated certificate of incorporation. The Company allocates undistributed earnings attributable to common stock between the common stock classes on a one-to-one basis when computing net income (loss) per share. As a result, basic and diluted net income (loss) per share of Class A common stock and share of Class B common stock are equivalent. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: As of March 31, 2023 2022 Unvested restricted common stock — 21,129 Options to purchase common stock 8,505,182 6,250,433 8,505,182 6,271,562
Recently issued and adopted accounting pronouncements	Recently adopted accounting pronouncements Effective January 1, 2023 , the Company adopted ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments for the year ended December 31, 2023. The new standard adjusts the accounting for assets held at amortized cost basis, including marketable securities accounted for as available for sale, and trade receivables. The standard eliminates the probable initial recognition threshold and requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. The adoption of this standard did no t have a material impact on the Company’s consolidated financial statements and related disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: As of March 31, 2023 2022 Unvested restricted common stock — 21,129 Options to purchase common stock 8,505,182 6,250,433 8,505,182 6,271,562

Marketable Securities (Tables)

Marketable Securities (Tables)	3 Months Ended
	Mar. 31, 2023
Marketable Securities [Abstract]
Summary of Marketable securities by Security	Marketable securities by security type consisted of the following (in thousands): March 31, 2023 Amortized Gross Gross Fair Value Commercial paper (due within one year) $ 125,640 $ 52 $ ( 89 ) $ 125,603 Corporate bonds (due within one year) 78,062 7 ( 244 ) 77,825 Government securities (due within one year) 46,261 27 ( 45 ) 46,243 U.S. treasury securities (due within one year) 43,236 15 ( 10 ) 43,241 Corporate bonds (due after one year through three years) 34,534 26 ( 119 ) 34,441 Government securities (due after one year through 27,979 67 ( 5 ) 28,041 U.S. treasury securities (due after one year through 4,937 16 — 4,953 $ 360,649 $ 210 $ ( 512 ) $ 360,347 December 31, 2022 Amortized Gross Gross Fair Value Commercial paper (due within one year) $ 90,685 $ 1 $ ( 93 ) $ 90,593 Corporate bonds (due within one year) 70,668 1 ( 332 ) 70,337 Government securities (due within one year) 19,267 22 ( 28 ) 19,261 U.S. treasury securities (due within one year) 28,560 — ( 23 ) 28,537 Corporate bonds (due after one year through two years) 5,262 — ( 18 ) 5,244 Government securities (due after one year through 16,409 — ( 24 ) 16,385 $ 230,851 $ 24 $ ( 518 ) $ 230,357

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of Fair Value Assets Measured on Recurring Basis	The following tables present the Company’s fair value hierarchy for its assets, which are measured at fair value on a recurring basis (in thousands): Fair Value Measurements at March 31, 2023: Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 79,079 $ — $ — $ 79,079 Marketable securities: Commercial paper — 125,603 — 125,603 Corporate bonds — 112,266 — 112,266 Government securities — 74,284 — 74,284 U.S. treasury securities — 48,194 — 48,194 $ 79,079 $ 360,347 $ — $ 439,426 Fair Value Measurements at December 31, 2022: Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 240,803 $ — $ — $ 240,803 Marketable securities: Commercial paper — 90,593 — 90,593 Corporate bonds — 75,581 — 75,581 Government securities — 35,646 — 35,646 U.S. treasury securities — 28,537 — 28,537 $ 240,803 $ 230,357 $ — $ 471,160

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2023
Accrued Liabilities, Current [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following (in thousands): March 31, 2023 December 31, 2022 Accrued employee compensation and benefits $ 2,132 $ 4,852 Accrued external research and development expenses 7,469 5,944 Other 987 1,490 $ 10,588 $ 12,286

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2023
Share-based Payment Arrangement [Abstract]
Summary of stock-based compensation expenses	The Company recorded stock-based compensation expense related to common stock options and restricted common stock in the following expense categories of its consolidated statements of operations and comprehensive loss (in thousands): Three Months Ended March 31, 2023 2022 Research and development expenses $ 2,513 $ 947 General and administrative expenses 2,858 1,258 $ 5,371 $ 2,205

Nature of Business and Basis _2

Nature of Business and Basis of Presentation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		12 Months Ended
	Nov. 03, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net loss		$ 25,192	$ 17,549	$ 81,900
Accumulated deficit		$ 185,269		$ 160,077
Common Class A [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued during period shares new shares	7,895,522
Shares issued price per share	$ 33.50
Net proceeds from issuance of common stock in follow-on public offering after underwriting discounts and commission and offering costs	$ 247,900
Common Class A [Member] | Over-Allotment Option [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued during period shares new shares	1,029,850

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	8,505,182	6,271,562
Unvested restricted common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	0	21,129
Options to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	8,505,182	6,250,433

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2023 USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Marketable securities credit loss	$ 0
ASU 2016-13 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true
Change in accounting principle, accounting standards update, adoption date	Jan. 01, 2023
Change in accounting principle, accounting standards update, immaterial effect [true false]	true

Marketable Securities - Summary

Marketable Securities - Summary of Marketable securities by Security (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Marketable Securities [Line Items]
Amortized Cost	$ 360,649	$ 230,851
Gross Unrealized Gains	210	24
Gross Unrealized Losses	(512)	(518)
Fair Value	360,347	230,357
Commercial paper [Member] | Due within one year [Member]
Marketable Securities [Line Items]
Amortized Cost	125,640	90,685
Gross Unrealized Gains	52	1
Gross Unrealized Losses	(89)	(93)
Fair Value	125,603	90,593
Government Securities [Member] | Due from one to two years [Member]
Marketable Securities [Line Items]
Amortized Cost	27,979	16,409
Gross Unrealized Gains	67
Gross Unrealized Losses	(5)	(24)
Fair Value	28,041	16,385
Government Securities [Member] | Due within one year [Member]
Marketable Securities [Line Items]
Amortized Cost	46,261	19,267
Gross Unrealized Gains	27	22
Gross Unrealized Losses	(45)	(28)
Fair Value	46,243	19,261
US Treasury Securities [Member] | Due from one to two years [Member]
Marketable Securities [Line Items]
Amortized Cost	4,937
Gross Unrealized Gains	16
Fair Value	4,953
US Treasury Securities [Member] | Due within one year [Member]
Marketable Securities [Line Items]
Amortized Cost	43,236	28,560
Gross Unrealized Gains	15
Gross Unrealized Losses	(10)	(23)
Fair Value	43,241	28,537
Corporate bonds [Member] | Due from one to two years [Member]
Marketable Securities [Line Items]
Amortized Cost		5,262
Gross Unrealized Losses		(18)
Fair Value		5,244
Corporate bonds [Member] | Due from one to three years [Member]
Marketable Securities [Line Items]
Amortized Cost	34,534
Gross Unrealized Gains	26
Gross Unrealized Losses	(119)
Fair Value	34,441
Corporate bonds [Member] | Due within one year [Member]
Marketable Securities [Line Items]
Amortized Cost	78,062	70,668
Gross Unrealized Gains	7	1
Gross Unrealized Losses	(244)	(332)
Fair Value	$ 77,825	$ 70,337

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value Assets Measured on Recurring Basis (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	$ 360,347	$ 230,357
Fair Value Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	439,426	471,160
Fair Value Recurring [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	79,079	240,803
Fair Value Recurring [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	125,603	90,593
Fair Value Recurring [Member] | Corporate bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	112,266	75,581
Fair Value Recurring [Member] | Government securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	74,284	35,646
Fair Value Recurring [Member] | U.S. treasury securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	48,194	28,537
Fair Value Recurring [Member] | Fair value, inputs, level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	79,079	240,803
Fair Value Recurring [Member] | Fair value, inputs, level 1 [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	79,079	240,803
Fair Value Recurring [Member] | Fair value, inputs, level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	360,347	230,357
Fair Value Recurring [Member] | Fair value, inputs, level 2 [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	125,603	90,593
Fair Value Recurring [Member] | Fair value, inputs, level 2 [Member] | Corporate bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	112,266	75,581
Fair Value Recurring [Member] | Fair value, inputs, level 2 [Member] | Government securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	74,284	35,646
Fair Value Recurring [Member] | Fair value, inputs, level 2 [Member] | U.S. treasury securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	$ 48,194	$ 28,537

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value transfers in or out of Level 3	$ 0	$ 0

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Accrued Liabilities, Current [Abstract]
Accrued employee compensation and benefits	$ 2,132	$ 4,852
Accrued external research and development expenses	7,469	5,944
Other	987	1,490
Total Accrued expenses	$ 10,588	$ 12,286

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ in Millions			3 Months Ended
	Jan. 01, 2023	Jul. 28, 2021	Mar. 31, 2023
Unrecognized compensation cost related to common stock options			$ 67.1
Share based payment weighted average period			3 years 2 months 12 days
2021 Stock Option and Incentive Plan [Member]
Number of additional authorized shares reserved	2,833,447
2021 Stock Option and Incentive Plan [Member] | Common Class A [Member]
Shares available for future issuance			6,360,795
2021 Employee Stock Purchase Plan [Member]
Shares available for future issuance			1,419,192
Number of additional authorized shares reserved	473,064
Number of shares issued			0
2021 Employee Stock Purchase Plan [Member] | Common Class A [Member]
Percentage of purchase price of each shares purchased		85%
Service Based [Member] | Employees and Directors [Member]
Service-based vesting options granted			2,134,430
Aggregate fair value of restricted stock, vested			$ 41.7
Maximum [Member] | 2021 Stock Option and Incentive Plan [Member] | Class A and Class B Common Stock [Member]
Share based compensation arrangement by share based payment award annual increase percentage		5%
Maximum [Member] | 2021 Employee Stock Purchase Plan [Member] | Common Class A [Member]
Share based compensation arrangement by share based payment award annual increase amount		473,064
Maximum [Member] | 2021 Employee Stock Purchase Plan [Member] | Class A and Class B Common Stock [Member]
Share based compensation arrangement by share based payment award annual increase percentage		1%

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock-Based Compensation Expenses (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	$ 5,371	$ 2,205
Research and Development Expenses [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	2,513	947
General and Administrative Expenses [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	$ 2,858	$ 1,258

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Accrued liability	$ 0		$ 0
Maximum [Member]
Short-term lease cost	$ 100,000	$ 100,000

Defined Contribution Plan - Add

Defined Contribution Plan - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Defined contribution plan, employer discretionary contribution amount	$ 0.3	$ 0.1
Defined contribution plan employer matching contribution percent of match	6%

Related Parties - Additional In

Related Parties - Additional Information (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Deerfield And Scientific Founder [Member]
Related party amounts paid	$ 0		$ 0
Consulting Agreement [Member]
Related party amounts paid	100,000	$ 100,000
Accounts payable, related parties	$ 0
Consulting Agreement [Member] | Maximum [Member]
Accounts payable, related parties			$ 100,000